From January to September, the export of traditional Chinese medicines totaled 961 million U.S. dollars, a year-on-year increase of 13.7%. Among them, the export of Chinese Herbal Pieces was 388 million US dollars, up 17.2% year-on-year; the export of Chinese patent medicine was 125 million US dollars, up 13.8% year-on-year; the export of extracts was 385 million US dollars, an increase of 9.1% year-on-year; the export of health products was 62.67 million US dollars, up 21.3% year-on-year. The main reasons for the increase in export volume are first, the international market's further recognition of Chinese medicine, and the market demand is still growing steadily. Second, in the first half of the year, the exchange rate of the renminbi is still rising, and the export value in dollar terms has increased. Third, domestic Chinese medicine As the price of wood increases, the operating costs such as manpower and environmental protection increase, causing export prices to rise. The international financial crisis will have an adverse impact on the export of Chinese medicines. In September, Chinese medicines exports increased by 12.9% in the same month, which is lower than the growth rate of nearly one percentage point in the first three quarters. The adverse impact of the financial crisis will have a follow-up response. In October, the China Chamber of Commerce for the Import and Export of Medicines and Health Products carried out a questionnaire survey on the impact of the financial crisis on Chinese medicine exports. A total of 45 companies responded. 40% of companies think that they will have serious impact, 18% think that they have little impact, and 27% say they don’t. Main reasons: Export orders have shrunk, export prices have fallen, and the risk of foreign exchange collection has increased. The financial crisis also affected the sharp decline in exports to the United States. From January to September, it exported 93.31 million U.S. dollars to U.S. Chinese medicines, a decrease of 19.3% year-on-year. The impact of the financial crisis on Chinese medicine exports may not be gradually increased. The growth rate of Chinese medicine exports will slow down significantly in the fourth quarter, especially the export of extracts. The European Union and the United States are the main markets for my extracts, which account for about 50% of my extract exports. The EU and U.S. imports of extracts are mainly used for botanicals, dietary supplements, natural cosmetics and other industrial uses due to dietary supplements and The market elasticity of natural cosmetics is in great demand, and the financial crisis will lead to shrinking consumption. The demand for raw materials for extracts from the international market will drop. Exports of extracts from major markets in Japan will also decline. The main export market of Chinese patent medicines in China is currently in Asia. Hong Kong accounts for about 40% of my total exports, Japan accounts for about 10% of total exports, and exports to the United States and to the European Union are relatively small, as Chinese patent medicine exports to Asia are mainly in the form of pharmaceuticals. As a result, rigid demand is predominant. Therefore, exports of proprietary Chinese medicines are much less affected by the financial crisis than extracts. The market demand for Chinese herbal medicines and decoction pieces is relatively stable, but domestic quality inspections currently have a greater impact on the exports of Chinese herbal medicines and decoction pieces. Many companies are unable to normalize their performance externally. In August, exports fell by 7.1%. In September, exports only increased by 5.3%. Future export growth will also be greatly affected. The market demand in Asia, Europe, and Latin America is strong. North America and Oceania are affected by the financial crisis and their demand is shrinking. In January-September, Chinese medicine exported 628 million U.S. dollars to Asia, accounting for 65.4% of China's total export volume of Chinese medicines, an increase of 15.9% year-on-year, and nearly 3 percentage points higher than the global export growth rate. In particular, exports to Japan reached US$189 million in January-September, accounting for 20% of my total exports, which has far exceeded my exports to Hong Kong and grew by 18.4% year-on-year, the highest growth rate in the same period in recent years. Exports to Vietnam, Malaysia, Taiwan and Singapore have all increased significantly. Exports to Vietnam reached 52.19 million U.S. dollars, an increase of 78.5% year-on-year; Malaysia's exports to the United States were 39.32 million U.S. dollars, up 67.1% year-on-year. However, exports to Hong Kong and South Korea have declined to varying degrees. Hong Kong's local market has been less affected by the financial crisis. However, due to the international financial crisis, re-exports have declined. From January to September, I exported 150 million U.S. dollars to Hong Kong, a 5.8% year-on-year decrease. , Has retired to the second place in my Chinese medicine export market. Affected by the increase of standards for pesticide residues and heavy metals of Chinese herbal medicines and Chinese Herbal Medicines, the export of traditional Chinese medicines to South Korea fell, with exports of 70.93 million US dollars in the first nine months of the year, a year-on-year decrease of 4.4%.
Product categories of Instant Noodle Machine, The capacity of this instant noodle production line is 11000 bags/8 hours.
We are specialized manufacturers with 15 years of extruder experience, we have the perfect after-sales service and technical support. Look forward to your cooperation!
Instant Noodle Making Machine,Instant Noodle Production Line,Instant Noodle Equipment,Mini Instant Noodles Machinery
Jinan Chenyang Technology Co., Ltd. , https://www.cyricestrawproductionline.com